Invesco
TRDA icon

Invesco’s Entrada Therapeutics TRDA Stock Holding History

Invesco’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326K Buy
44,344
+2,418
+6% +$23.2K ﹤0.01% 3410
2026
Q1 		$529K Buy
41,926
+893
+2% +$10.2K ﹤0.01% 3142
2025
Q4 		$422K Buy
41,033
+11,958
+41% +$101K ﹤0.01% 3264
2025
Q3 		$169K Buy
29,075
+6,682
+30% +$39.1K ﹤0.01% 3599
2025
Q2 		$150K Buy
22,393
+5,702
+34% +$45.9K ﹤0.01% 3584
2025
Q1 		$151K Buy
16,691
+5,187
+45% +$64.6K ﹤0.01% 3568
2024
Q4 		$199K Buy
+11,504
New +$208K ﹤0.01% 3518
2024
Q3 		– Sell
-45,456
Closed -$648K – 3882
2024
Q2 		$648K Buy
45,456
+35,344
+350% +$502K ﹤0.01% 3164
2024
Q1 		$143K Sell
10,112
-7,184
-42% -$102K ﹤0.01% 3703
2023
Q4 		$261K Buy
+17,296
New +$256K ﹤0.01% 3477
2022
Q4 		– Sell
-95,209
Closed -$1.5M – 4066
2022
Q3 		$1.5M Buy
+95,209
New +$1.21M ﹤0.01% 2755

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Invesco's TRDA Position: Q2 2026 in Review

Invesco increased its Entrada Therapeutics (TRDA) stake by 5.8% in Q2 2026, buying an estimated $23.2K and bringing the position to 44,344 shares worth $326K. The position accounts for ﹤0.01% of the portfolio, ranked #3410.

Invesco first reported a position in TRDA in Q3 2022 and has held it in 11 quarters since. The position peaked at $1.5M in Q3 2022. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Invesco held 44,344 shares of Entrada Therapeutics worth $326K as of Q2 2026.
  • Invesco bought 2,418 Entrada Therapeutics shares in Q2 2026, an estimated $23.2K.
  • Entrada Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3410 holding.
  • Invesco first reported a position in Entrada Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • Invesco's Entrada Therapeutics position peaked at $1.5M in Q3 2022.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.